FMI
TRVI icon

F/M Investments’s Trevi Therapeutics TRVI Stock Holding History

F/M Investments’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.37M Buy
234,208
+2,606
+1% +$37.9K 0.22% 85
2026
Q1 		$2.76M Sell
231,602
-9,881
-4% -$111K 0.18% 88
2025
Q4 		$3.02M Buy
+241,483
New +$2.79M 0.11% 195

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

F/M Investments's TRVI Position: Q2 2026 in Review

F/M Investments increased its Trevi Therapeutics (TRVI) stake by 1.1% in Q2 2026, buying an estimated $37.9K and bringing the position to 234,208 shares worth $4.37M. The position accounts for 0.22% of the portfolio, ranked #85.

F/M Investments first reported a position in TRVI in Q4 2025 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • F/M Investments held 234,208 shares of Trevi Therapeutics worth $4.37M as of Q2 2026.
  • F/M Investments bought 2,606 Trevi Therapeutics shares in Q2 2026, an estimated $37.9K.
  • Trevi Therapeutics made up 0.22% of F/M Investments's portfolio in Q2 2026, its #85 holding.
  • F/M Investments first reported a position in Trevi Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.